Skip to main content
SpringerLink
Log in

A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

We designed a novel transcatheter arterial infusion chemotherapy (TAI) using iodized oil (lipiodol) and degradable starch microspheres (DSM) for hepatocellular carcinoma (HCC) patients. In this study, we investigated the efficacy of TAI using lipiodol and DSM in a prospective randomized trial.

Methods

We randomly divided 45 patients with HCC into 3 groups: TAI using lipiodol (lipiodol group, n = 15), TAI using DSM (DSM group, n = 15), and TAI using lipiodol and DSM (lipiodol + DSM group, n = 15). In the lipiodol group, a mixture of cisplatin and lipiodol was administered. In the DSM group, a mixture of cisplatin and DSM was administered. In the lipiodol + DSM group, a mixture of cisplatin and lipiodol was administered, followed by DSM.

Results

The response rates were 40% in the lipiodol group, 53.4% in the DSM group, and 80% in the lipiodol + DSM group, respectively. The response rate tended to improve in the lipiodol + DSM group (lipiodol group vs. lipiodol + DSM group, P = 0.07). The median progression-free survival time was 177 days in the lipiodol group, 287 days in the DSM group, and 377 days in the lipiodol + DSM group. The progression-free survival in the lipiodol + DSM group was significantly better than those in the DSM group (P = 0.020) and the lipiodol group (P = 0.035). There were no serious adverse effects among the 3 groups.

Conclusions

TAI using lipiodol and DSM was superior to TAI using lipiodol only and TAI using DSM only because of improvements in therapeutic effects and progression-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  2. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.

    Article  PubMed  Google Scholar 

  3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–34.

    Article  PubMed  Google Scholar 

  4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe. 1980–2004. Hepatology. 2008;48:137–45.

    Article  PubMed  Google Scholar 

  5. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

    Article  PubMed  Google Scholar 

  6. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458–64.

    Article  PubMed  CAS  Google Scholar 

  7. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188:79–83.

    PubMed  CAS  Google Scholar 

  8. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer. 2001;91:1342–8.

    Article  PubMed  CAS  Google Scholar 

  9. Todo S, Furukawa H, Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451–61.

    Article  PubMed  Google Scholar 

  10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  PubMed  CAS  Google Scholar 

  11. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.

    Article  PubMed  CAS  Google Scholar 

  12. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.

    Article  PubMed  Google Scholar 

  13. Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27:1578–83.

    Article  PubMed  CAS  Google Scholar 

  14. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Thong D, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol. 1998;29:129–34.

    Article  PubMed  CAS  Google Scholar 

  15. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  16. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  PubMed  CAS  Google Scholar 

  17. Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Moriyama N, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol. 2001;176:681–8.

    PubMed  CAS  Google Scholar 

  18. Yoon HJ, Kim JH, Kim KA, Lee IS, Ko GY, Song HY, et al. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol. 2010;65:271–7.

    Article  PubMed  Google Scholar 

  19. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24–31.

    Article  PubMed  CAS  Google Scholar 

  20. Forsberg JO. Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres. Experiments on rats. Acta Chir Scand. 1978;144:275–81.

    PubMed  CAS  Google Scholar 

  21. Lindell B, Aronsen KF, Rothman U. Repeated arterial embolization of rat livers by degradable microspheres. Eur Surg Res. 1977;9:347–56.

    Article  PubMed  CAS  Google Scholar 

  22. Dakhil S, Ensminger W, Cho K, Niederhuber J, Doan K, Wheeler R. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer. 1982;50:631–5.

    Article  PubMed  CAS  Google Scholar 

  23. Ensminger WD, Gyves JW, Stetson P, Walker-Andrews S. Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res. 1985;45:4464–7.

    PubMed  CAS  Google Scholar 

  24. Taguchi T. Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet. 1994;26:275–91.

    Article  PubMed  CAS  Google Scholar 

  25. Carr BI, Zajiko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol. 1997;24(suppl 6):S6-97–9.

    Google Scholar 

  26. Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol. 2003;26:159–64.

    Article  PubMed  CAS  Google Scholar 

  27. Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, et al. Chemoocclusion vs. chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol. 2006;32:201–7.

    Article  PubMed  CAS  Google Scholar 

  28. Yamasaki T, Saeki I, Harima Y, Okita K, Segawa M, Yamaguchi Y, et al. The pilot study: a novel transarterial chemoembolization using degradable starch microspheres for hepatocellular carcinoma (in Japanese with English abstract). Kanzo. 2008;49:25–7.

    Article  Google Scholar 

  29. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  PubMed  CAS  Google Scholar 

  30. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edn. Tokyo: Kanehara, 2009 (in Japanese).

  31. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–15.

    Article  PubMed  Google Scholar 

  32. Kanematsu M, Hoshi H, Imaeda T, Murakami T, Inaba Y, Yokoyama R, et al. Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography. AJR Am J Roentgenol. 1997;168:1193–8.

    PubMed  CAS  Google Scholar 

  33. Okusaka T, Okada S, Ishii H, Ikeda M, Nakasuka H, Nagahama H, et al. Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma. Oncology. 1998;55:276–83.

    Article  PubMed  CAS  Google Scholar 

  34. Takayasu K, Arri S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000;175:699–704.

    PubMed  CAS  Google Scholar 

  35. Okusaka T, Okada S, Ueno H, Ikeda M, Yoshimori M, Shimada K, et al. Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology. 2000;58:293–9.

    Article  PubMed  CAS  Google Scholar 

  36. National Cancer Institute (2009) Common Terminology Criteria for Adverse Events v.4.0. National Cancer Institute, Bethesda

  37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–81.

    Article  Google Scholar 

  38. Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564–8.

    Article  PubMed  CAS  Google Scholar 

  39. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474–83.

    Article  PubMed  CAS  Google Scholar 

  40. Vogl TJ, Trapp M, Shroeder H, Mack M, Schuster A, Schmitt J, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success—results from a liver transplantation center. Radiology. 2000;214:349–57.

    Google Scholar 

  41. Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, et al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int. 2007;6:259–66.

    PubMed  CAS  Google Scholar 

  42. Kanematsu M. Transcatheter arterial chemoembolization therapy with epirubicin hydrochloride, mitomycin C-iohexol-lipiodol emulsion (EMILE) for hepatocellular carcinoma. J Gastroenterol. 1995;30:215–23.

    Google Scholar 

  43. Sigurdson ER, Ridge JA, Daly JM. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch Surg. 1986;121:1277–81.

    Article  PubMed  CAS  Google Scholar 

  44. Nakamura H, Hashimoto T, Oi H, Sawada S. Iodized oil in the portal vein after arterial embolization. Radiology. 1988;167:415–7.

    PubMed  CAS  Google Scholar 

  45. Kan Z, Ivancev K, Hägerstrand I, Chuang VP, Lunderquist A. In vivo microscopy of the liver after injection of lipiodol into the hepatic artery and portal vein in the rat. Acta Radiol. 1989;30:419–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (Grant No. 20591478).

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan

    Takahiro Yamasaki, Satoe Hamabe, Issei Saeki, Yohei Harima, Yuhki Yamaguchi, Koichi Uchida, Shuji Terai & Isao Sakaida

Authors
  1. Takahiro Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoe Hamabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Issei Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yohei Harima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuhki Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koichi Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuji Terai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Isao Sakaida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Yamasaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamasaki, T., Hamabe, S., Saeki, I. et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol 46, 359–366 (2011). https://doi.org/10.1007/s00535-010-0306-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-010-0306-5

Keywords

Search

Navigation